Axis Reimbursement Expands Services Into US Market
Consultancies in the pharmaceutical sector can look to this expansion model for scaling advisory services internationally.
Updated on Oct. 30, 2026 in Healthcare
Live Poll
Do you trust small consulting firms to navigate the complexities of international healthcare markets successfully?
Axis Reimbursement, a firm that assists pharmaceutical companies with state reimbursement strategies, expanded into the United States in June 2026. This move follows the company's 2023 entry into the UK market.
Why it matters
The firm seeks to scale by helping drug manufacturers navigate complex reimbursement schemes in new international markets. Expanding into the US provides access to the world's largest pharmaceutical market for clinical and cost-effectiveness advisory services.
The firm generated €3.3 million in revenue in 2025 and projects growth to €5 million in 2026, supported by a team of 20 permanent staff and 10 contractors. The company currently holds 6 percent of the UK market.
The players
Axis Reimbursement
A Dublin-based consultancy that helps pharmaceutical firms secure state reimbursement through clinical data support.
Enterprise Ireland
The Irish state agency responsible for helping domestic businesses expand internationally through office support and trade services.
Brenda Dooley
The founder of Axis Reimbursement who established the firm in 2011.
The details
Axis Reimbursement provides specialized consultancy to help pharmaceutical companies prove clinical and cost-effectiveness to state payers. By securing office space and trade show support through Enterprise Ireland, the firm replicates the strategy used for its 2023 UK expansion. This model allows the lean team to establish a footprint in foreign markets without the overhead of full-scale local administrative infrastructure.
Timeline
2011: Axis Reimbursement was founded.
2023: The firm entered the UK market.
June 2026: Operations expanded into the United States.
Market Landscape
The firm is following the documented trend of boutique consultancies leveraging state-backed trade support to enter high-value pharmaceutical markets. This expansion mirrors the broader industry move toward specialized market access advisory services to navigate complex global healthcare pricing.
Operators in the pharmaceutical services space should monitor the effectiveness of government-backed support programs like Enterprise Ireland for rapid international scaling. The firm's ability to maintain a lean structure of 20 staff while expanding across two continents provides a benchmark for resource allocation.
The takeaway
Service firms looking to scale internationally should evaluate the impact of utilizing state-funded trade agency resources for initial market entry. Reviewing Axis Reimbursement's 6 percent UK market penetration offers a comparative metric for assessing the success of their US entry strategy.
Further reading
For broader trends in global health, visit Healthcare.
Source note: This article includes information reported by Business Post.
Live Poll
Do you trust small consulting firms to navigate the complexities of international healthcare markets successfully?
